Targacept buoyed by AZ's commitment to Alzheimer's program

Shares of Targacept ($TGRT) were buoyed this morning by the news that AstraZeneca ($AZN) is committing its support for the experimental Alzheimer's drug AZD1446, which is moving into a midstage study. That's good news for Targacept, which has been forced to concede recently that the first two late-stage studies for a depression drug partnered with AstraZeneca have failed. Release

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.